PNC Financial Services Group
LUCD icon

PNC Financial Services Group’s Lucid Diagnostics LUCD Stock Holding History

PNC Financial Services Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174 Sell
163
-13
-7% -$14 ﹤0.01% 5112
2026
Q1 		$202 Buy
176
+6
+4% +$8 ﹤0.01% 5031
2025
Q4 		$185 Buy
+170
New +$190 ﹤0.01% 4988

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

PNC Financial Services Group's LUCD Position: Q2 2026 in Review

PNC Financial Services Group reduced its Lucid Diagnostics (LUCD) stake by 7.4% in Q2 2026, selling an estimated $14 and leaving 163 shares worth $174. The position accounts for ﹤0.01% of the portfolio, ranked #5112.

PNC Financial Services Group first reported a position in LUCD in Q4 2025 and has held it in 3 quarters since. The position peaked at $202 in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • PNC Financial Services Group held 163 shares of Lucid Diagnostics worth $174 as of Q2 2026.
  • PNC Financial Services Group sold 13 Lucid Diagnostics shares in Q2 2026, an estimated $14.
  • Lucid Diagnostics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #5112 holding.
  • PNC Financial Services Group first reported a position in Lucid Diagnostics in Q4 2025 and has held it in 3 quarters since.
  • PNC Financial Services Group's Lucid Diagnostics position peaked at $202 in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.